https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Cytotherapy 2006;8(4):318-26
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Cytotherapy 2006;8(4):318-262006-01-01 00:00:002019-02-15 08:45:56Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Clin Neurosurg 2006;53:345-51
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Clin Neurosurg 2006;53:345-512006-01-01 00:00:002019-02-15 08:59:51Mahaley Clinical Research Award: chemosensitization of glioma through dendritic cell vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Cytotherapy 2006;8(6):580-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Cytotherapy 2006;8(6):580-82006-01-01 00:00:002019-02-15 09:03:05Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Immunol. Res. 2006;36(1-3):265-74
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Immunol. Res. 2006;36(1-3):265-742006-01-01 00:00:002019-02-15 09:15:12Understanding and exploiting dendritic cells in human immunodeficiency virus infection using the nonhuman primate model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / J Gene Med 2006 Jan;8(1):3-17
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / J Gene Med 2006 Jan;8(1):3-172006-01-01 00:00:002019-02-15 09:15:18From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-01 / Adv. Immunol. 2006;90:243-95
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-01 / Adv. Immunol. 2006;90:243-952006-01-01 00:00:002019-02-15 09:19:49Immunity to melanoma antigens: from self-tolerance to immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-15 / Clin. Cancer Res. 2005 Dec;11(24 Pt 1):8808-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-15 / Clin. Cancer Res. 2005 Dec;11(24 Pt 1):8808-152005-12-15 00:00:002019-02-15 09:25:39Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-15 / Clin. Cancer Res. 2005 Dec;11(24 Pt 1):8763-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-15 / Clin. Cancer Res. 2005 Dec;11(24 Pt 1):8763-722005-12-15 00:00:002019-02-15 09:25:40Natural killer cells license dendritic cell cross-presentation of B lymphoma cell–associated antigens
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-06 / Cancer Immunol. Immunother. 2006 Oct;55(10):1209-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-06 / Cancer Immunol. Immunother. 2006 Oct;55(10):1209-182005-12-06 00:00:002019-02-15 09:19:47Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-12-01 / Int J Hyperthermia 2005 Dec;21(8):723-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-12-01 / Int J Hyperthermia 2005 Dec;21(8):723-92005-12-01 00:00:002019-02-15 09:17:45Thermal regulation of lymphocyte trafficking: hot spots of the immune response
